NCT03281629

Brief Summary

In a double-blinded, randomized, parallel controlled design, patients with schizophrenia spectrum disorder will be exposed to active or sham repetitive transcranial magentic stimulation (TMS) which was guided by functional magnetic resonance image (MRI). Smoking reduction/cessation and brain functional connectivity changes will be assessed at baseline, different stages of rTMS and/or follow-ups.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 1, 2017

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 13, 2017

Completed
1.1 years until next milestone

Study Start

First participant enrolled

October 19, 2018

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2021

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2022

Completed
11 months until next milestone

Results Posted

Study results publicly available

January 18, 2023

Completed
Last Updated

January 18, 2023

Status Verified

December 1, 2022

Enrollment Period

2.4 years

First QC Date

September 1, 2017

Results QC Date

September 23, 2022

Last Update Submit

December 21, 2022

Conditions

Keywords

Transcranial magnetic stimulationschizophreniaMRIsmoking

Outcome Measures

Primary Outcomes (1)

  • Cigarette Per Day

    Cigarette per day (CPD) is measured to index smoking reduction and cessation. The change of CPD between baseline and end-of-treatment (1-month time point), 3-month follow up (4-month time point) and 6-month follow up (7-month time point) are reported. Negative values of the change of CPD indicate reductions in cigarette consumption.

    7 months

Secondary Outcomes (4)

  • Functional Magnetic Resonance Imaging (fMRI)

    4 months

  • Cotinine

    1 month

  • End-expired Carbon Monoxide (CO)

    1 month

  • Normalized Gamma Power of Auditory Static State Response (ASSR) From Electroencephalography (EEG)

    4 months

Study Arms (2)

Active TMS stimulation

ACTIVE COMPARATOR

Real active rTMS stimulation.

Device: Active TMS stimulation

Sham TMS stimulation

SHAM COMPARATOR

Sham repetitive TMS stimulation.

Device: Sham TMS stimulation

Interventions

Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.

Active TMS stimulation

Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.

Sham TMS stimulation

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Male and female between ages 18-60
  • Ability to give written informed consent (age 18 or above)
  • Smoking in the last one year or more and average cigarette per day ≥ 5 in the past 4 weeks.
  • For patient participants, Evaluation to Sign Consent (ESC) above10.

You may not qualify if:

  • Any history of seizures
  • Had smoking cessation treatment, clinical trial, or nicotine replacements within the past four weeks.
  • Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence.
  • Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, stroke, CNS infection or tumor, other significant brain neurological conditions.
  • Taking \> 400 mg clozapine/day
  • Failed TMS screening questionnaire
  • Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.
  • History of head injury with loss of consciousness over 10 minutes; history of brain surgery
  • Can not refrain from using alcohol and/or marijuana 24 hours or more \& cigarette smoking one hour or more prior to experiments.
  • Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self report; or by positive pregnancy test).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Maryland, Baltimore

Baltimore, Maryland, 21228, United States

Location

MeSH Terms

Conditions

Smoking CessationTobacco Use DisorderSchizophreniaSmoking

Condition Hierarchy (Ancestors)

Health BehaviorBehaviorSubstance-Related DisordersChemically-Induced DisordersMental DisordersSchizophrenia Spectrum and Other Psychotic Disorders

Results Point of Contact

Title
Dr. Xiaoming Du
Organization
Maryland Psychiatric Research Center, University of Maryland School of Medicine

Study Officials

  • Xiaoming Du, MD

    University of Maryland, Baltimore

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professsor

Study Record Dates

First Submitted

September 1, 2017

First Posted

September 13, 2017

Study Start

October 19, 2018

Primary Completion

February 28, 2021

Study Completion

February 15, 2022

Last Updated

January 18, 2023

Results First Posted

January 18, 2023

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations